---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-245186"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-05-28T20:05:08+00:00"
generated_at: "2026-05-28T21:23:13.220771+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viridian pre-pays $55.1M Hercules Capital loan, terminates credit facility

## Summary
- Paid ~$55.1M to satisfy all principal, accrued interest and fees under Loan Agreement with Hercules Capital.
- Original term loan allowed up to $300M; company borrowed $50M at floating rate (min 8.95%, cap 9.45%).
- Loan termination effective May 27, 2026; all obligations discharged and covenants eliminated.
- Interest-only payments were due through Oct 2029/2030 depending on milestones; now fully extinguished.

## SEC filing metadata
- accession: 0001193125-26-245186
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-05-28T20:05:08+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526245186/0001193125-26-245186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526245186/d111506d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-245186
- JSON: https://secwatch.observer/filing/0001193125-26-245186.json
- Plain text: https://secwatch.observer/filing/0001193125-26-245186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.